XML 71 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Medytox/Allergan Settlement Agreements and Daewoong Arrangement (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 25, 2021
shares
Mar. 23, 2021
USD ($)
$ / shares
Feb. 28, 2021
USD ($)
shares
Feb. 18, 2021
USD ($)
$ / shares
Mar. 31, 2021
shares
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
$ / shares
Dec. 31, 2020
USD ($)
$ / shares
Sep. 15, 2025
Sep. 15, 2024
Sep. 15, 2023
Loss Contingencies [Line Items]                            
Loss contingency accrual                   $ 0 $ 0      
Payments for legal settlements                     $ 48,421,000      
Common stock, par value (in dollars per share) | $ / shares                   $ 0.00001 $ 0.00001      
Forecast                            
Loss Contingencies [Line Items]                            
Share issuance agreement, percentage of share dispose per year                       75.00% 50.00% 25.00%
Common Stock                            
Loss Contingencies [Line Items]                            
Issuance of common stock in connection with litigation settlement (in shares) | shares     6,762,652                      
Daewoong Agreement                            
Loss Contingencies [Line Items]                            
Long-term purchase commitment, amount   $ 25,500,000                        
Contingent milestone payment   10,500,000                        
Daewoong Convertible Note | Convertible Debt                            
Loss Contingencies [Line Items]                            
Convertible debt   $ 40,779,000                        
Conversion price (in dollars per share) | $ / shares   $ 13.00                        
Daewoong Convertible Note | Convertible Debt | Maximum                            
Loss Contingencies [Line Items]                            
Common stock shares beneficially own percentage   0.0999                        
Daewoong Convertible Note | Convertible Debt | Common Stock                            
Loss Contingencies [Line Items]                            
Conversion of common shares (in shares) | shares 3,136,869       3,136,869                  
Intellectual Property Disputes, Jeuveau                            
Loss Contingencies [Line Items]                            
Loss contingency accrual     $ 35,000,000 $ 35,000,000             $ 35,000,000      
Settlement agreement, payment terms (in years)       2 years                    
Payments for legal settlements             $ 15,000,000     $ 15,000,000        
Common stock, par value (in dollars per share) | $ / shares       $ 0.00001                    
Intellectual Property Disputes, Jeuveau | Subsequent Event                            
Loss Contingencies [Line Items]                            
Payments for legal settlements           $ 15,000                
Intellectual Property Disputes, Jeuveau | Forecast                            
Loss Contingencies [Line Items]                            
Payments for legal settlements               $ 5,000,000 $ 15,000,000